2023 annual financial data
Foghorn Therapeutics Inc. 2023 Operating margin
Foghorn Therapeutics Inc. 2023 operating margin with verified reported values.
Direct answer
Operating margin was -315.93%.
Operating income was -107,906,000 USD and net income was -98,426,000 USD.
Operating cash flow was -118,106,000 USD.
Get free Foghorn Therapeutics Inc. email updates.
Bullstory sends one daily email when new analysis or important company news is available.
Verified data
- Revenue
- 34,155,000 USD
- Operating income
- -107,906,000 USD
- Net income
- -98,426,000 USD
- Operating cash flow
- -118,106,000 USD